Retinal Venous Pressure and ET-1 in Patients With Diabetes Mellitus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01771835|
Recruitment Status : Completed
First Posted : January 18, 2013
Last Update Posted : January 18, 2013
|Condition or disease|
Diabetic retinopathy and maculopathy are the main causes of visual loss. Hyperglycemia as the main risk factor of diabetic retinopathy induced damage to retinal capillaries. These in turn lead to hypoxia in the tissue and promote the release of VEGF (vascular endothelial growth factor) , which in turn increases the vascular pathology. Simultaneously, there is an increased expression of endothelin (ET-1). Endothelin increases vascular tone and regulates the micro-and macro-vascular remodeling.
In ocular blood flow perfusion pressure plays an important role. While in healthy eyes a spontaneous retinal venous pulsation is frequently observed, this is significantly less frequent in diseased eyes. An increased venous pressure lowers the ocular perfusion pressure, and increases the transmural pressure. A measurement of the retinal venous pressure and the hormone ET-1 in the blood will give us a better knowledge of the circulatory changes and their relationship to diabetes.
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||Measurement of Retinal Venous Pressure and Endothelin-1 in Patients With Diabetes Mellitus|
|Study Start Date :||August 2011|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||November 2012|
Patients with diabetes mellitus type I + II, without diabetic retinopathy
- Quantification of retinal venous pressure (RVP) [ Time Frame: 30 minutes ]
- Quantification of ET-1 in correlation with RVP [ Time Frame: 30 minutes ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01771835
|University of Basel, Dept. of Ophthalmology|
|Basel, Switzerland, 4031|
|Study Director:||Josef Flammer, MD||University of Basel, Dept. of Ophthalmology|